Prevention	prevention	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
with	with	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
:	:	O	O	O	O
preliminary	preliminary	O	O	O	O
findings	findings	O	O	O	O
from	from	O	O	O	O
the	the	O	O	O	O
Italian	italian	O	O	O	O
randomised	randomised	O	O	O	O
trial	trial	O	O	O	O
among	among	O	O	O	O
hysterectomised	hysterectomised	O	O	O	O
women	women	O	O	O	O
.	.	O	O	O	O

Italian	italian	O	O	O	O
Tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
Prevention	prevention	O	O	O	O
Study	study	O	O	O	O
.	.	O	O	O	O

BACKGROUND	background	O	O	O	O
:	:	O	O	O	O
Tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
is	is	O	O	O	O
a	a	O	O	O	O
candidate	candidate	O	O	O	O
chemopreventive	chemopreventive	O	O	O	O
agent	agent	O	O	O	O
in	in	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
although	although	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
endometrial	endometrial	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Therefore	therefore	O	O	O	O
we	we	O	O	O	O
did	did	O	O	O	O
a	a	O	O	O	O
trial	trial	O	O	O	O
in	in	O	O	O	O
hysterectomised	hysterectomised	O	O	O	O
women	women	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
as	as	O	O	O	O
a	a	O	O	O	O
chemopreventive	chemopreventive	O	O	O	O
.	.	O	O	O	O

METHODS	methods	O	O	O	O
:	:	O	O	O	O
In	in	O	O	O	O
October	october	O	O	O	O
,	,	O	O	O	O
1992	1992	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
started	started	O	O	O	O
a	a	O	O	O	O
double-blind	double-blind	O	O	O	O
placebo-controlled	placebo-controlled	O	O	O	O
,	,	O	O	O	O
randomised	randomised	O	O	O	O
trial	trial	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
in	in	O	O	O	O
women	women	O	O	O	O
(	(	O	O	O	O
mainly	mainly	O	O	O	O
in	in	O	O	O	O
Italy	italy	O	O	O	O
)	)	O	O	O	O
who	who	O	O	O	O
did	did	O	O	O	O
not	not	O	O	O	O
have	have	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
and	and	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
had	had	O	O	O	O
a	a	O	O	O	O
hysterectomy	hysterectomy	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
were	were	O	O	O	O
randomised	randomised	O	O	O	O
to	to	O	O	O	O
receive	receive	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
20	20	O	O	O	O
mg	mg	O	O	OTHERS	I
per	per	O	O	O	O
day	day	O	O	O	O
or	or	O	O	O	O
placebo	placebo	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
orally	orally	O	O	O	O
for	for	O	O	O	O
5	5	O	O	O	O
years	years	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
original	original	O	O	O	O
plan	plan	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
follow	follow	O	O	O	O
the	the	O	O	O	O
intervention	intervention	O	O	O	O
phase	phase	O	O	O	O
by	by	O	O	O	O
5	5	O	O	O	O
years	years	O	O	O	O
'	'	O	O	O	O
follow-up	follow-up	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
June	june	O	O	O	O
,	,	O	O	O	O
1997	1997	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
trialists	trialists	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
data-monitoring	data-monitoring	O	O	O	O
committee	committee	O	O	O	O
decided	decided	O	O	O	O
to	to	O	O	O	O
end	end	O	O	O	O
recruitment	recruitment	O	O	O	O
primarily	primarily	O	O	O	O
because	because	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
number	number	O	O	O	O
of	of	O	O	O	O
women	women	O	O	O	O
dropping	dropping	O	O	O	O
out	out	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

Recruitment	recruitment	O	O	O	O
ended	ended	O	O	O	O
on	on	O	O	O	O
July	july	O	O	O	O
11	11	O	O	O	O
,	,	O	O	O	O
1997	1997	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
will	will	O	O	O	O
continue	continue	O	O	O	O
as	as	O	O	O	O
planned	planned	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
primary	primary	O	O	O	O
endpoints	endpoints	O	O	O	O
are	are	O	O	O	O
the	the	O	O	O	O
occurrence	occurrence	O	O	O	O
of	of	O	O	O	O
and	and	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
from	from	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
preliminary	preliminary	O	O	O	O
interim	interim	O	O	O	O
analysis	analysis	O	O	O	O
is	is	O	O	O	O
based	based	O	O	O	O
on	on	O	O	O	O
intention-to-treat	intention-to-treat	O	O	O	O
.	.	O	O	O	O

FINDINGS	findings	O	O	O	O
:	:	O	O	O	O
5408	5408	O	O	O	O
women	women	O	O	O	O
were	were	O	O	O	O
randomised	randomised	O	O	O	O
;	;	O	O	O	O
participating	participating	O	O	O	O
women	women	O	O	O	O
have	have	O	O	O	O
a	a	O	O	O	O
median	median	O	O	O	O
follow-up	follow-up	O	O	O	O
of	of	O	O	O	O
46	46	O	O	O	O
months	months	O	O	O	O
for	for	O	O	O	O
major	major	O	O	O	O
endpoints	endpoints	O	O	O	O
.	.	O	O	O	O

41	41	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
so	so	O	O	O	O
far	far	O	O	O	O
;	;	O	O	O	O
there	there	O	O	O	O
have	have	O	O	O	O
been	been	O	O	O	O
no	no	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
from	from	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
.	.	O	O	O	O

There	there	O	O	O	O
is	is	O	O	O	O
no	no	O	O	O	O
difference	difference	O	O	O	O
in	in	O	O	O	O
breast-cancer	breast-cancer	O	O	O	O
frequency	frequency	O	O	O	O
between	between	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
(	(	O	O	O	O
22	22	O	O	O	O
cases	cases	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
19	19	O	O	O	O
)	)	O	O	O	O
arms	arms	O	O	O	O
.	.	O	O	O	O

There	there	O	O	O	O
is	is	O	O	O	O
a	a	O	O	O	O
statistically	statistically	O	O	O	O
significant	significant	O	O	O	O
reduction	reduction	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
among	among	O	O	O	O
women	women	O	O	O	O
receiving	receiving	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
who	who	O	O	O	O
also	also	O	O	O	O
used	used	O	O	O	O
hormone-replacement	hormone-replacement	O	O	O	O
therapy	therapy	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
trial	trial	O	O	O	O
:	:	O	O	O	O
among	among	O	O	O	O
390	390	O	O	O	O
women	women	O	O	O	O
on	on	O	O	O	O
such	such	O	O	O	O
therapy	therapy	O	O	O	O
and	and	O	O	O	O
allocated	allocated	O	O	O	O
to	to	O	O	O	O
placebo	placebo	O	O	O	O
,	,	O	O	O	O
we	we	O	O	O	O
found	found	O	O	O	O
eight	eight	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
compared	compared	O	O	O	O
with	with	O	O	O	O
one	one	O	O	O	O
case	case	O	O	O	O
among	among	O	O	O	O
362	362	O	O	O	O
women	women	O	O	O	O
allocated	allocated	O	O	O	O
to	to	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Compared	compared	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
placebo	placebo	O	O	O	O
group	group	O	O	O	O
,	,	O	O	O	O
there	there	O	O	O	O
was	was	O	O	O	O
a	a	O	O	O	O
significantly	significantly	O	O	O	O
increased	increased	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
vascular	vascular	O	O	OTHERS	I
events	events	O	O	OTHERS	I
and	and	O	O	O	O
hypertriglyceridaemia	hypertriglyceridaemia	O	O	OTHERS	I
among	among	O	O	O	O
women	women	O	O	O	O
on	on	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

INTERPRETATION	interpretation	O	O	O	O
:	:	O	O	O	O
Although	although	O	O	O	O
this	this	O	O	O	O
preliminary	preliminary	O	O	O	O
analysis	analysis	O	O	O	O
has	has	O	O	O	O
low	low	O	O	O	O
power	power	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
this	this	O	O	O	O
cohort	cohort	O	O	O	O
of	of	O	O	O	O
women	women	O	O	O	O
at	at	O	O	O	O
low-to-normal	low-to-normal	O	O	O	O
risk	risk	O	O	O	O
of	of	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
postulated	postulated	O	O	O	O
protective	protective	O	O	O	O
effects	effects	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
are	are	O	O	O	O
not	not	O	O	O	O
yet	yet	O	O	O	O
apparent	apparent	O	O	O	O
.	.	O	O	O	O

Women	women	O	O	O	O
using	using	O	O	O	O
hormone-replacement	hormone-replacement	O	O	O	O
therapy	therapy	O	O	O	O
appear	appear	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
benefited	benefited	O	O	O	O
from	from	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

There	there	O	O	O	O
were	were	O	O	O	O
no	no	O	O	O	O
deaths	deaths	O	DISEASE	OTHERS	I
from	from	O	O	O	O
breast	breast	O	DISEASE	OTHERS	I
cancer	cancer	O	DISEASE	OTHERS	I
recorded	recorded	O	O	O	O
in	in	O	O	O	O
women	women	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
study	study	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
essential	essential	O	O	O	O
to	to	O	O	O	O
continue	continue	O	O	O	O
follow-up	follow-up	O	O	O	O
to	to	O	O	O	O
quantify	quantify	O	O	O	O
the	the	O	O	O	O
long-term	long-term	O	O	O	O
risks	risks	O	O	O	O
and	and	O	O	O	O
benefits	benefits	O	O	O	O
of	of	O	O	O	O
tamoxifen	tamoxifen	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
.	.	O	O	O	O

